Mechanism
PCSK9 and LPA (bivalent, dual-target)
Assets acting on this target.
- Class
- Bi-valent GalNAc-conjugated siRNA co-targeting PCSK9 and LPA mRNA
- Pathway
- Simultaneous RNAi-mediated silencing of PCSK9 and LPA (apo(a)) mRNA in hepatocytes, lowering both LDL-C (via preserved LDL receptor recycling) and Lp(a) (via reduced apo(a) synthesis) in a single molecule